Theratechnologies Expects EGRIFTA SV Supply Disruption To Affect Revenues In Q4 Of 2024
Portfolio Pulse from Benzinga Newsdesk
Theratechnologies anticipates a supply disruption of EGRIFTA SV, which is expected to impact revenues in Q4 2024. Despite this, the company remains confident in achieving strong Adjusted EBITDA for the current fiscal year, with more details to be shared in their Q3 results in October.
September 17, 2024 | 9:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Theratechnologies expects a supply disruption of EGRIFTA SV to impact Q4 2024 revenues. However, the company is optimistic about achieving strong Adjusted EBITDA for the current fiscal year.
The anticipated supply disruption of EGRIFTA SV is likely to negatively impact Theratechnologies' revenues in Q4 2024, which could lead to a short-term negative sentiment on the stock. However, the company's confidence in achieving strong Adjusted EBITDA for the current fiscal year may mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100